Numbers first: a GLP-1 receptor agonist · 2.5 mg/mL · eight weeks.
I would rather be corrected now than propagate something wrong.
I am specifically not interested in a testimonial; I am interested in a measurement.
Is this actually true, and what is the evidence?
eight weeks is 56 days and, on a weekly schedule, 8 stopper punctures out of one vial at 2.5 mg/mL. Set the chemical question aside for a moment, because the puncture count is the one with a convention attached: 56 days is 2 times the twenty-eight days conventionally allowed for a preserved multi-dose preparation once it has been entered. Chemically, 2.5 mg/mL is high enough that adsorption to the glass is a rounding error and low enough that it is not protecting you from anything. What 8 withdrawals do add is 8 opportunities to introduce air, 8 coring events on the same stopper, and a headspace that grows with every draw — none of which show up on a certificate and all of which are avoided by splitting into aliquots at reconstitution.
Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.
Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.
| Pathway | Dominant when | Detected by |
|---|---|---|
| Deamidation | Solution, neutral to alkaline pH | RP-HPLC, +1 Da on MS |
| Oxidation | Light, trace metals, peroxides | RP-HPLC, +16 Da on MS |
| Hydrolysis | Solution, extremes of pH | RP-HPLC, fragment masses |
| Aggregation | Agitation, interfaces, high concentration | SEC, visual haze; often invisible on RP-HPLC |
| Freeze-concentration damage | Freeze-thaw of buffered solution | SEC, loss of recovered content |
The part that matters: hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.
Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.
Sequence determines which pathways apply, so general statements are general.
Sequence decides which pathways are even available. Check the residues.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThe short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.
Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.
Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.
Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.
Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.
At dilute concentrations, suspect adsorption before you suspect chemistry.
edited 27 May 2024 by tenth_of_a_unit — removed a claim I could not source
The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.
A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.
Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.
The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.
Swirl, never shake. Aggregation is a handling problem more than a time problem.
On the detail: this is answerable from the chemistry rather than from anecdote, which is unusual and welcome.
Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.
Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.
Nothing here is medical advice, and research-use compounds are not approved for human use.
A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.
It helps to be literal here: asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.
Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.
The caveat is that "within specification" and "unchanged" are different claims. A vial can lose a few per cent of content and still be usable for its purpose while no longer matching its certificate.
Cold, dry, dark, still. Those four words cover most of the mitigation.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.